Genmab.
Danish healthcare company
- Reports this week
- 1
- Active events
- 1
- Connections
- 50
What's happening
Active this week
Earlier this month
-
AbbVie, Genmab, and Sarah Cannon Research Institute announced the joint development of Epkinly for DLBCL treatment.Well supported7 reports1 development inside
-
Genmab, a Danish biotechnology company, granted stock units and warrants via its Board of Directors on September 1, 2026.Some support1 report
One to three months ago
-
Truist Financial started coverage on Genmab shares, and TD Cowen raised rating and price target for the company, which trades on Nasdaq.Some support2 reports
-
CSG, Novo Nordisk, and Genmab were confirmed as constituents of the STOXX 600 index.Some support3 reports
-
Genmab listed its shares on the stock exchange on August 6, 2026.Some support1 report
-
Genmab, headquartered in Denmark, is issuing interim financial reports and monitoring the Japanese market.Some support1 report
-
AbbVie and Genmab will engage global regulatory authorities regarding their joint development efforts.Well supported8 reports1 development inside
Gone quiet
No new reports in 90+ days-
A collaboration between AbbVie, Genmab, and Nxera Pharma has seen joint trial success, leading to potential milestone payments and favorable opinions from the European Commission.Some support1 report
-
A partnership between Microsoft, Tevogen Bio Holdings Inc., Databricks, and Genmab was announced on August 23, 2025, accelerating therapeutic discovery and development.Some support6 reports1 development inside
-
Genmab is headquartered in Copenhagen.Well supported9 reports
-
Genmab A/S ADR is now listed on the NASDAQ stock exchange.Some support8 reports
-
Genmab, a Denmark-based biotechnology company headquartered in Copenhagen, partnered with Janssen for commercialization.Some support1 report
-
Genmab's Board of Directors granted stock units and warrants on June 1, 2026.Some support2 reports
-
FDA granted Breakthrough Therapy Designation for Genmab's Rina-S, while the company also faces potential challenges from Trump's tariffs.Well supported4 reports
-
Greg Mueller joined Genmab as Executive Vice President, moving from AstraZeneca.Speculative1 report
-
Morgan Stanley assigned an Equal-Weight rating to Genmab on July 3, 2025.Speculative1 report
-
Genmab reported increased royalties from its DARZALEX collaboration with Johnson & Johnson, while UBS maintained a Buy rating on the company.Well supported5 reports
-
Steve Cohen recommended Genmab as a buy, and Truist Securities raised its price target for the company.Some support1 report
-
Genmab, Amgen, Immunocore, Merck, and Zymeworks are key players in the bispecific antibodies market.Some support2 reports
-
Scott Cenci previously worked at Genmab, Biogen, Zoetis, and Pfizer.Some support1 report
-
Genmab faces uncertainty regarding regulatory approvals from the FDA.Some support3 reports
-
Genmab, Bolt Biotherapeutics, and Toray are advancing multiple development candidates, with collaborations with Toray progressing and a Phase 1 study underway in Australia.Some support1 report
-
Pfizer and Genmab are collaborating on TIVDAK, which combines Genmab's antibody with Pfizer's ADC technology.Some support3 reports
No events began in the chosen period. Widen it, or reset.
What's reaching Genmab
Events traced to Genmab, step by step, newest first- JNJ's strong financials may boost Genmab's royalty revenueJNJ's strong financials may boost Genmab's royalty revenuePossible
- AbbVie's new therapy approvals strengthen Genmab partnershipAbbVie's new therapy approvals strengthen joint development partnership with GenmabLikely
- Genmab may gain from strong Darzalex sales at Johnson & JohnsonGenmab may benefit from strong sales of Johnson & Johnson's DarzalexLikely
Around Genmab this week
News at the entities that move Genmab most-
Johnson & Johnson StructuralJohnson & Johnson joins the USMN initiative.Moves Genmab
-
AbbVie StructuralAbbVie's drug Emrelis received approval in Brazil, alongside statistics on the high incidence of lung cancer in the country.Moves Genmab
-
FDA StructuralFDA, LabCorp, and Charles River Laboratories formed a collaboration to evaluate the potential for medicine abuse.Moves Genmab
-
board of directors StructuralCounty officials from seven different counties serve on the NDACo Board.Moves Genmab
-
Novartis TransactionalSean Maenpaa, with experience at Novartis and Celgene, was appointed SVP Business Development at Clovis Oncology.Moves Genmab
-
Nasdaq StructuralCompany Q783794 made an announcement originating from Lafox, Illinois, and is listed on Nasdaq.Moves Genmab
Connections
The 22 strongest of 50, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
AbbVie Structural
AbbVie and Genmab maintain a formal partnership for joint drug development, clinical trials, and commercialization, including profit-sharing.
-
Johnson & Johnson Structural
Genmab receives royalty revenue from Johnson & Johnson's commercialization of daratumumab under an exclusive license agreement.
-
FDA Structural
The FDA structurally regulates Genmab's drug development, reviewing submissions and granting designations.
-
board of directors Structural
The Board of Directors formally grants stock units and warrants to Genmab as part of its corporate governance.
-
Janssen Transactional
Genmab and Janssen have entered into a partnership regarding the commercialization of the product daratumumab.
-
Jan Van de Winkel Structural
Jan Van de Winkel serves as the CEO and President of Genmab.
-
Novartis Transactional
Genmab receives royalty revenue from Novartis stemming from their collaboration on Kesimpta.
-
Nasdaq Structural
Genmab is a publicly traded company whose shares are listed and traded on the Nasdaq exchange.
Show all 22 connections
-
Danish Business Authority Structural
Genmab's operation requires formal registration and compliance with the standards set by the Danish Business Authority.
-
Renaissance Technologies Transactional
Renaissance Technologies has made a current investment in Genmab stock.
-
FED Operational
Genmab's strong financial results influence market sentiment regarding the Federal Reserve's rate hike expectations.
-
TD Cowen Transactional
TD Cowen, a financial research firm, issued a rating upgrade to Buy on Genmab.
-
Denmark Shared context
Genmab is consistently described as being headquartered in or operating from Denmark.
-
Europe Structural
Genmab is included in the STOXX 600 index, which represents the market structure of Europe.
-
LinkedIn Mentioned together
Genmab utilizes LinkedIn as a platform for corporate presence and communication.
-
Copenhagen Shared context
Genmab is headquartered and operates from Copenhagen.
-
Utrecht Shared context
Genmab maintains R&D facilities located within the city of Utrecht.
-
Truist Financial Mentioned together
Truist Financial began providing investment coverage and analysis on Genmab shares.
-
Reuters Mentioned together
Reuters, a major global news agency, reports on the stock performance of the biotech company Genmab.
-
MarketBeat Mentioned together
MarketBeat provides consensus rating data regarding Genmab.
-
Asia Shared context
Genmab is mentioned in the context of corporate earnings reports related to market sentiment in Asia.
-
Michael Schmidt Mentioned together
No evidence links Michael Schmidt to Genmab in the provided timeline.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
2 eventsAugust 2026
3 eventsShow 1 earlier month
June 2026
18 events- AbbVie, Genmab, and Sarah Cannon Research Institute announced the joint development of Epkinly for DLBCL treatment.
- AbbVie and Genmab will engage global regulatory authorities regarding their joint development efforts.
- A collaboration between AbbVie, Genmab, and Nxera Pharma has seen joint trial success, leading to potential milestone payments and favorable opinions from the European Commission.
- A partnership between Microsoft, Tevogen Bio Holdings Inc., Databricks, and Genmab was announced on August 23, 2025, accelerating therapeutic discovery and development.
- Genmab is headquartered in Copenhagen.
- Genmab A/S ADR is now listed on the NASDAQ stock exchange.
- Genmab, a Denmark-based biotechnology company headquartered in Copenhagen, partnered with Janssen for commercialization.
- Genmab's Board of Directors granted stock units and warrants on June 1, 2026.
- FDA granted Breakthrough Therapy Designation for Genmab's Rina-S, while the company also faces potential challenges from Trump's tariffs.
- Greg Mueller joined Genmab as Executive Vice President, moving from AstraZeneca.
- Morgan Stanley assigned an Equal-Weight rating to Genmab on July 3, 2025.
- Genmab reported increased royalties from its DARZALEX collaboration with Johnson & Johnson, while UBS maintained a Buy rating on the company.
- Steve Cohen recommended Genmab as a buy, and Truist Securities raised its price target for the company.
- Genmab, Amgen, Immunocore, Merck, and Zymeworks are key players in the bispecific antibodies market.
- Scott Cenci previously worked at Genmab, Biogen, Zoetis, and Pfizer.
- Genmab faces uncertainty regarding regulatory approvals from the FDA.
- Genmab, Bolt Biotherapeutics, and Toray are advancing multiple development candidates, with collaborations with Toray progressing and a Phase 1 study underway in Australia.
- Pfizer and Genmab are collaborating on TIVDAK, which combines Genmab's antibody with Pfizer's ADC technology.